These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16404704)

  • 41. The effect of the anticoagulation regimen on endothelial-related coagulation in cardiac surgery patients.
    Boldt J; Schindler E; Welters I; Wittstock M; Stertmann WA; Hempelmann G
    Anaesthesia; 1995 Nov; 50(11):954-60. PubMed ID: 8678251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass.
    Spanier TB; Chen JM; Oz MC; Edwards NM; Kisiel W; Stern DM; Rose EA; Schmidt AM
    J Thorac Cardiovasc Surg; 1998 Nov; 116(5):860-9. PubMed ID: 9806393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hirudin in heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Focus on thrombin: alternative anticoagulants.
    Merry AF
    Semin Cardiothorac Vasc Anesth; 2007 Dec; 11(4):256-60. PubMed ID: 18270188
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma.
    Gerotziafas GT; Bara L; Bloch MF; Makris PE; Samama MM
    Blood Coagul Fibrinolysis; 1998 Oct; 9(7):571-80. PubMed ID: 9863704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The use of PEG-Hirudin in chronic hemodialysis monitored by the Ecarin Clotting Time: influence on clotting of the extracorporeal system and hemostatic parameters.
    Ulbricht K; Bucha E; Pöschel KA; Stein G; Wolf G; Nowak G
    Clin Nephrol; 2006 Mar; 65(3):180-90. PubMed ID: 16550749
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass.
    Terrell MR; Walenga JM; Koza MJ; Pifarré R
    Ann Thorac Surg; 1996 Aug; 62(2):506-11. PubMed ID: 8694614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The direct thrombin inhibitor hirudin.
    Greinacher A; Warkentin TE
    Thromb Haemost; 2008 May; 99(5):819-29. PubMed ID: 18449411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the effects of heparin and hirudin on thrombin binding to the normal and the de-endothelialized rabbit aorta in vitro.
    Hatton MW; Moar SL
    Thromb Haemost; 1991 Aug; 66(2):208-12. PubMed ID: 1771613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
    Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
    Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats.
    Hauptmann J; Brüggener E; Markwardt F
    Haemostasis; 1987; 17(6):321-8. PubMed ID: 3428717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Platelet functions in recombinant hirudin-anticoagulated blood.
    Glusa E; Markwardt F
    Haemostasis; 1990; 20(2):112-8. PubMed ID: 2363746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of the clotting system: heparin-coated versus non coated systems for extracorporeal circulation.
    Urlesberger B; Zobel G; Rödl S; Dacar D; Friehs I; Leschnik B; Muntean W
    Int J Artif Organs; 1997 Dec; 20(12):708-12. PubMed ID: 9506788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The efficiency of anti-activated factor X and anti-activated factor II anticoagulants.
    Stief TW
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):265-9. PubMed ID: 17413764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model.
    Sakai M; Ohteki H; Narita Y; Naitoh K; Natsuaki M; Itoh T
    Cardiovasc Surg; 1999 Mar; 7(2):187-94. PubMed ID: 10353669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antithrombin effects of native and recombinant hirudins.
    Markwardt F; Stürzebecher J; Glusa E
    Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].
    Devignes J; de Maistre E; Grosjean S; Walter AF; Hacquard M; Mulot A; Longrois D; Carteaux JP; Lecompte T
    Ann Biol Clin (Paris); 2005; 63(2):201-8. PubMed ID: 15771978
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dependence of human platelet functional responses on divalent cations: aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents.
    Lages B; Weiss HJ
    Thromb Haemost; 1981 Apr; 45(2):173-9. PubMed ID: 6789496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of thrombin generation in recalcified plasma.
    Stief TW
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):751-60. PubMed ID: 17982316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.